Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. SNY
stocks logo

SNY

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
11.14B
+5.47%
0.798
+16.96%
10.12B
+2.27%
0.989
-3.22%
10.77B
+7.71%
0.000
-100%
Estimates Revision
The market is revising Downward the revenue expectations for Sanofi (SNY) for FY2025, with the revenue forecasts being adjusted by -1.49% over the past three months. During the same period, the stock price has changed by 1.81%.
Revenue Estimates for FY2025
Revise Downward
down Image
-1.49%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-0.86%
In Past 3 Month
Stock Price
Go Up
up Image
+1.81%
In Past 3 Month
Wall Street analysts forecast SNY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SNY is 63.50 USD with a low forecast of 58.00 USD and a high forecast of 69.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
Wall Street analysts forecast SNY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SNY is 63.50 USD with a low forecast of 58.00 USD and a high forecast of 69.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 50.740
sliders
Low
58.00
Averages
63.50
High
69.00
Current: 50.740
sliders
Low
58.00
Averages
63.50
High
69.00
Oppenheimer
Trevor Allred
Outperform
maintain
$60 -> $62
2025-11-06
Reason
Oppenheimer
Trevor Allred
Price Target
$60 -> $62
2025-11-06
maintain
Outperform
Reason
Oppenheimer analyst Trevor Allred raised the firm's price target on Dianthus (DNTH) to $62 from $60 and keeps an Outperform rating on the shares. The firm notes Dianthus reported a Q3 net loss of $37M, in line with its $36M estimate. Oppenheimer's focus is narrowing onto CIDP, as claseprubart's Phase 3 enrollment looks to be garnering subjects from Sanofi's (SNY) riliprubart and other therapeutic options. The firm expects CIDP results to garner more investor attention.
Jefferies
Buy
initiated
€100
2025-10-27
Reason
Jefferies
Price Target
€100
2025-10-27
initiated
Buy
Reason
Jefferies assumed coverage of Sanofi with a Buy rating and EUR 100 price target, calling it the analyst's EU Pharma top pick. Valued at about a 15% discount to the sector, the firm believes the perception that Sanofi lacks a pipeline to offset the 2031 Dupixent patent expiry is "incorrect," with upcoming catalysts over the next 12 months set to build confidence, the analyst tells investors.
Morgan Stanley
Equal Weight -> Overweight
upgrade
$56 -> $58
2025-09-08
Reason
Morgan Stanley
Price Target
$56 -> $58
2025-09-08
upgrade
Equal Weight -> Overweight
Reason
Morgan Stanley upgraded Sanofi to Overweight from Equal Weight with a price target of $58, up from $56. The firm believes the recent pullback in the shares brings an attractive entry point. The clarity on amlitelimab removes an overhang on the stock, and the equity story can shift from research and development execution back to Sanofi's earnings momentum in the near-term, the analyst tells investors in a research note. Morgan Stanley believes margin expansion in 2026 now looks possible for the company, supported by continued sales momentum.
Deutsche Bank
Emmanuel Papadakis
Hold
to
Buy
upgrade
2025-09-02
Reason
Deutsche Bank
Emmanuel Papadakis
Price Target
2025-09-02
upgrade
Hold
to
Buy
Reason
Deutsche Bank analyst Emmanuel Papadakis upgraded Sanofi to Buy from Hold with a price target of EUR 110, up from EUR 90. The firm expects the Phase 3 results for amlitelimab in atopic dermatitis to be positive. With a de-rated multiple, Sanofi shares offer an attractive risk/reward into the readout, the analyst tells investors in a research note.
JPMorgan
Richard Vosser
Neutral -> Overweight
upgrade
2025-08-08
Reason
JPMorgan
Richard Vosser
Price Target
2025-08-08
upgrade
Neutral -> Overweight
Reason
JPMorgan analyst Richard Vosser upgraded Sanofi to Overweight from Neutral with a price target of EUR 105, down from EUR 110. The firm sees positive risk/reward into the company's data readouts as it believes little pipeline value is being priced into the shares. Sanofi is undervalued even in the unlikely event of these assets being worth zero, the analyst tells investors in a research note. JPMorgan says Sanofi is trading at a 20% discount to the sector.
Deutsche Bank
Emmanuel Papadakis
Hold
downgrade
2025-08-05
Reason
Deutsche Bank
Emmanuel Papadakis
Price Target
2025-08-05
downgrade
Hold
Reason
Deutsche Bank analyst Emmanuel Papadakis lowered the firm's price target on Sanofi to EUR 90 from EUR 100 and keeps a Hold rating on the shares.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Sanofi SA (SNY.O) is 10.74, compared to its 5-year average forward P/E of 10.44. For a more detailed relative valuation and DCF analysis to assess Sanofi SA 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PE
10.44
Current PE
10.74
Overvalued PE
13.79
Undervalued PE
7.09

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average EV/EBITDA
9.12
Current EV/EBITDA
8.66
Overvalued EV/EBITDA
9.81
Undervalued EV/EBITDA
8.42

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
3.14
Current PS
88.66
Overvalued PS
9.25
Undervalued PS
-2.96
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 231.75% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

SNY News & Events

Events Timeline

(ET)
2025-11-14
10:00:40
Sanofi's French facility flagged for quality control problems by ANSM
select
link
2025-11-11 (ET)
2025-11-11
16:27:07
Richard Pazdur Named Director of CDER by FDA
select
link
2025-11-07 (ET)
2025-11-07
08:13:24
Sanofi and Regeneron announce achievement of all primary endpoints in LIBERTY-AFRS-AIMS study
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
11-14SeekingAlpha
Sanofi and Lilly Among This Week's EU Drug Recommendation Successes

  • EMA Endorsements: The European Medicines Agency (EMA) expert panel endorsed 10 new medicines, including a diabetes drug from Sanofi and a breast cancer drug from Eli Lilly, pending final approval from the European Commission.

  • Teizeild Approval: Sanofi's Teizeild (teplizumab) received a positive opinion for delaying severe type 1 diabetes in patients aged eight and older, potentially becoming the first disease-modifying therapy for T1D in the EU.

  • Eli Lilly's Inluriyo: Eli Lilly's breast cancer therapy Inluriyo (imlunestrant) was backed by the EMA panel as a late-line treatment for adults with specific types of breast cancer, awaiting European Commission approval.

  • Dawnzera for HAE: Ionis Pharma and Otsuka's Dawnzera received a positive opinion for routine prevention of hereditary angioedema attacks in patients aged 12 and older, with a final decision expected in Q1 2026.

[object Object]
Preview
1.0
11-12SeekingAlpha
CDC Vaccine Panel Scheduled to Convene in December to Discuss Hepatitis B Vaccination Vote

  • CDC Meeting on Hepatitis B Vaccination: The U.S. CDC's Advisory Committee on Immunization Practices (ACIP) will meet on December 4-5 to discuss potential changes to the Hepatitis B vaccination schedule for children, including a vote on whether to delay the first shot for babies born to mothers who test negative for the virus.

  • Previous Vote Postponement: In a prior meeting, the ACIP postponed a vote on the Hepatitis B dosing schedule, with 11 out of 12 panel members favoring the delay, while the committee chair opposed it.

[object Object]
Preview
6.5
11-11NASDAQ.COM
Accenture, Sanofi, and Dell Featured in the Zacks Analyst Blog

  • Accenture's Performance: Accenture plc has underperformed in the IT services sector, facing rising competition and integration risks from acquisitions, but its growth strategy and strong cash position make it appealing for dividend-seeking investors.

  • Sanofi's Growth and Challenges: Sanofi has outperformed the pharmaceutical industry, driven by strong demand for its drug Dupixent and a robust vaccine portfolio, although it faces challenges from generic competition and pipeline setbacks.

  • Dell Technologies' Demand Surge: Dell Technologies has seen strong performance due to high demand for AI servers, supported by partnerships with major companies like NVIDIA and Google, despite facing challenges in the traditional PC market and supply chain costs.

  • Zacks Research Insights: Zacks Equity Research provides daily insights and stock recommendations, highlighting the latest reports on major companies and offering strategies that have historically outperformed the S&P 500.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Sanofi SA (SNY) stock price today?

The current price of SNY is 50.74 USD — it has decreased -2.01 % in the last trading day.

arrow icon

What is Sanofi SA (SNY)'s business?

Sanofi SA is a France-based healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.

arrow icon

What is the price predicton of SNY Stock?

Wall Street analysts forecast SNY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SNY is 63.50 USD with a low forecast of 58.00 USD and a high forecast of 69.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Sanofi SA (SNY)'s revenue for the last quarter?

Sanofi SA revenue for the last quarter amounts to NaN USD, decreased % YoY.

arrow icon

What is Sanofi SA (SNY)'s earnings per share (EPS) for the last quarter?

Sanofi SA. EPS for the last quarter amounts to USD, decreased % YoY.

arrow icon

What changes have occurred in the market's expectations for Sanofi SA (SNY)'s fundamentals?

The market is revising Downward the revenue expectations for Sanofi (SNY) for FY2025, with the revenue forecasts being adjusted by -1.49% over the past three months. During the same period, the stock price has changed by 1.81%.
arrow icon

How many employees does Sanofi SA (SNY). have?

Sanofi SA (SNY) has 84587 emplpoyees as of November 19 2025.

arrow icon

What is Sanofi SA (SNY) market cap?

Today SNY has the market capitalization of 126.04B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto Tracker
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free